Lack of cathepsin activities alter or prevent the development of lung granulomas in a mouse model of sarcoidosis

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  Samokhin, Andriy O ^a   Yves Gauthier, Jacques ^b   Percival, M David ^b   Brömme, Dieter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; OSTEOPONTIN; APOLIPOPROTEIN E; CATHEPSIN; COLLAGEN; CTSK PROTEIN, MOUSE; CTSL PROTEIN, MOUSE; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE; GIANT CELL; IMMUNOREACTIVITY; INCIDENCE; LUNG FIBROSIS; LUNG GRANULOMA; LUNG SARCOIDOSIS; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PREVALENCE; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN EXPRESSION; THYMUS HYPERPLASIA; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HYPERTROPHY; IMMUNOLOGY; LUNG; METABOLISM; MOUSE MUTANT; PATHOLOGY; SARCOIDOSIS; THYMUS; TIME;

ANIMALS; APOLIPOPROTEINS E; CATHEPSIN K; CATHEPSIN L; CATHEPSINS; CD4-POSITIVE T-LYMPHOCYTES; COLLAGEN; DISEASE MODELS, ANIMAL; GRANULOMA, RESPIRATORY TRACT; HYPERTROPHY; LUNG; MICE; MICE, KNOCKOUT; PROTEASE INHIBITORS; SARCOIDOSIS, PULMONARY; THYMUS GLAND; TIME FACTORS;

EID: 78651551355     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-13     Document Type: Article

References (40)

1. Wolters PJ, Chapman HA: Importance of lysosomal cysteine proteases in lung disease. Respir Res 2000, 1 (3): 170-177.
2. Buhling F, Waldburg N, Reisenauer A, Heimburg A, Golpon H, Welte T: Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation. Eur Respir J 2004, 23 (4): 620-628.
3. Hirakawa H, Pierce RA, Bingol-Karakoc G, Karaaslan C, Weng M, Shi GP, Saad A, Weber E, Mariani TJ, Starcher B, et al.: Cathepsin S deficiency confers protection from neonatal hyperoxia-induced lung injury. Am J Respir Crit Care Med 2007, 176 (8): 778-785.
4. Williams AS, Eynott PR, Leung SY, Nath P, Jupp R, De Sanctis GT, Resnick R, Adcock IM, Chung KF: Role of cathepsin S in ozone-induced airway hyperresponsiveness and inflammation. Pulm Pharmacol Ther 2009, 22 (1): 27-32.
5. Veillard F, Lecaille F, Lalmanach G: Lung cysteine cathepsins: intruders or unorthodox contributors to the kallikrein-kinin system? Int J Biochem Cell Biol 2008, 40 (6-7): 1079-1094.
6. Samokhin AO, Buhling F, Theissig F, Bromme D: ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis. Am J Pathol 2010, 176 (3): 1148-1156.
7. Lynch JP, Ma YL, Koss MN, White ES: Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007, 28 (1): 53-74.
8. Sharma OP: Sarcoidosis: a historical perspective. Clin Dermatol 2007, 25 (3): 232-241.
9. Lalmanach G, Diot E, Godat E, Lecaille F, Herve-Grepinet V: Cysteine cathepsins and caspases in silicosis. Biol Chem 2006, 387 (7): 863-870.
10. Diaz A, Willis AC, Sim RB: Expression of the proteinase specialized in bone resorption, cathepsin K, in granulomatous inflammation. Mol Med 2000, 6 (8): 648-659.
11. Buhling F, Reisenauer A, Gerber A, Kruger S, Weber E, Bromme D, Roessner A, Ansorge S, Welte T, Rocken C: Cathepsin K--a marker of macrophage differentiation? J Pathol 2001, 195 (3): 375-382.
12. Chilosi AM, Brizzolara D, Lami L, Pizzoli C, Gasperini F, Pecini C, Cipriani P, Zoccolotti P: Reading and Spelling Disabilities in Children With and Without a History of Early Language Delay: A Neuropsychological and Linguistic Study. Child Neuropsychol 2009, 1-23.
13. Serveau-Avesque C, Martino MF, Herve-Grepinet V, Hazouard E, Gauthier F, Diot E, Lalmanach G: Active cathepsins B, H, K, L and S in human inflammatory bronchoalveolar lavage fluids. Biol Cell 2006, 98 (1): 15-22.
14. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA: Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992, 267: 7258-7262.
15. Honey K, Rudensky AY: Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003, 3 (6): 472-482.
16. Hsing LC, Rudensky AY: The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev 2005, 207: 229-241.
17. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos JA, Ploegh H, Peters C, Rudensky AY: Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998, 280: 450-453.
18. Grunewald J, Eklund A: Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc 2007, 4 (5): 461-464.
19. Zissel G, Prasse A, Muller-Quernheim J: Sarcoidosis--immunopathogenetic concepts. Semin Respir Crit Care Med 2007, 28 (1): 3-14.
20. Gerke AK, Hunninghake G: The immunology of sarcoidosis. Clin Chest Med 2008, 29 (3): 379-390. vii
21. Noor A, Knox KS: Immunopathogenesis of sarcoidosis. Clin Dermatol 2007, 25 (3): 250-258.
22. Samokhin AO, Wong A, Saftig P, Bromme D: Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 2008, 200 (1): 58-68.
23. Saftig P, Wehmeyer O, Hunziker E, Jones S, Boyde A, Rommerskirch W, von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc Natl Acad Sci USA 1998, 95: 13453-13458.
24. Buhling F, Rocken C, Brasch F, Hartig R, Yasuda Y, Saftig P, Bromme D, Welte T: Pivotal role of cathepsin K in lung fibrosis. Am J Pathol 2004, 164 (6): 2203-2216.
25. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, Schmidt P, Schmahl W, Scherer J, Anton-Lamprecht I, et al.: Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. Faseb J 2000, 14 (13): 2075-2086.
26. Gauthier JY, Black WC, Courchesne I, Cromlish W, Desmarais S, Houle R, Lamontagne S, Li CS, Masse F, McKay DJ, et al.: The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett 2007, 17 (17): 4929-4933.
27. Xia L, Kilb J, Wex H, Lipyansky A, Breuil V, Stein L, Palmer JT, Dempster DW, Brömme D: Localization of rat cathepsin K in osteoclasts and resorption pits: Inhibition of bone resorption cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem 1999, 380: 679-687.
28. Kocks JR, Davalos-Misslitz AC, Hintzen G, Ohl L, Forster R: Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue. J Exp Med 2007, 204 (4): 723-734.
29. Riese RJ, Wolf P, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, Chapman HA: Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996, 4 (4): 357-366.
30. Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, Karp ER, De Sanctis GT, Ploegh HL, Chapman HA: Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998, 101 (11): 2351-2363.
31. Samokhin AO, Wilson S, Nho B, Lizame ML, Musenden OE, Bromme D: Cholate-containing high-fat diet induces the formation of multinucleated giant cells in atherosclerotic plaques of apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol 2010, 30 (6): 1166-1173.
32. Brömme D, Okamoto K, Wang BB, Biroc S: Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996, 271 (4): 2126-2132.
33. Nagai S, Handa T, Ito Y, Ohta K, Tamaya M, Izumi T: Outcome of sarcoidosis. Clin Chest Med 2008, 29 (3): 565-574. x
34. van Maarsseveen TC, Vos W, van Diest PJ: Giant cell formation in sarcoidosis: cell fusion or proliferation with non-division? Clin Exp Immunol 2009, 155 (3): 476-486.
35. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP, Frederik P, van der Made I, Daugherty A, Sijbers AM, et al.: Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006, 113 (1): 98-107.
36. Lutgens SP, Kisters N, Lutgens E, van Haaften RI, Evelo CT, de Winther MP, Saftig P, Daemen MJ, Heeneman S, Cleutjens KB: Gene profiling of cathepsin K deficiency in atherogenesis: profibrotic but lipogenic. J Pathol 2006, 210 (3): 334-343.
37. Helming L, Winter J, Gordon S: The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion. J Cell Sci 2009, 122 (Pt 4): 453-459.
38. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, McNeish JD, Eastman SE, Howard ED, Clarke SR, et al.: Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999, 10: 207-217.
39. Honey K, Nakagawa T, Peters C, Rudensky A: Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J Exp Med 2002, 195 (10): 1349-1358.
40. Lombardi G, Burzyn D, Mundinano J, Berguer P, Bekinschtein P, Costa H, Castillo LF, Goldman A, Meiss R, Piazzon I, et al.: Cathepsin-L influences the expression of extracellular matrix in lymphoid organs and plays a role in the regulation of thymic output and of peripheral T cell number. J Immunol 2005, 174 (11): 7022-7032.